A photo of Theodosia A. Kalfa.

Theodosia A. Kalfa, MD, PhD


  • Co-Director, Erythrocyte Diagnostic Laboratory
  • Professor, UC Department of Pediatrics

About

Additional Languages

Greek

Location

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Selected

VPS4A Mutations in Humans Cause Syndromic Congenital Dyserythropoietic Anemia due to Cytokinesis and Trafficking Defects. Seu, KG; Trump, LR; Emberesh, S; Lorsbach, RB; Johnson, C; Meznarich, J; Underhill, HR; Chou, ST; Sakthivel, H; Nassar, NN; et al. American Journal of Human Genetics. 2020; 107:1149-1156.

Selected

Red cell membrane disorders: structure meets function. Risinger, M; Kalfa, TA. Blood. 2020; 136:1250-1261.

Selected

Signaling and cytoskeletal requirements in erythroblast enucleation. Konstantinidis, DG; Pushkaran, S; Johnson, JF; Cancelas, JA; Manganaris, S; Harris, CE; Williams, DA; Zheng, Y; Kalfa, TA. Blood. 2012; 119:6118-6127.

Diagnosis and clinical management of red cell membrane disorders. Kalfa, TA. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2021; 2021:331-340.

Characterizing bulk rigidity of rigid red blood cell populations in sickle-cell disease patients. Gutierrez, M; Shamoun, M; Seu, KG; Tanski, T; Kalfa, TA; Eniola-Adefeso, O. Scientific Reports. 2021; 11.

SERF1 Is Required for G-CSF Resistance of Start-Codon Mutant ELANE Granulocytic Precursors. Nayak, RC; Trump, L; Emberesh, S; Lee, Y; Singh, AK; Wellendorf, AM; Horwitz, MS; Kalfa, TA; Lutzko, C; Cancelas, JA. Blood. 2021; 138:433-433.

Overexpression of Human TLR8 Causes Fatal Anemia in SLE-Prone Mice By Altering the Bone Marrow Erythropoietic Niche. Davidson, A; Maria, N; Papoin, J; Raparia, C; Sun, Z; Zhang, W; Kalfa, TA; Paulson, R; Blanc, L. Blood. 2021; 138:1989-1989.

Activation of Pyruvate Kinase-R with Etavopivat (FT-4202) Is Well Tolerated, Improves Anemia, and Decreases Intravascular Hemolysis in Patients with Sickle Cell Disease Treated for up to 12 Weeks. Brown, RC C; Saraf, SL; Cruz, K; Idowu, M; Kalfa, TA; Geib, J; Forsyth, S; Schroeder, P; Wu, E; Kelly, P; et al. Blood. 2021; 138:9-9.

Etavopivat, an Allosteric Activator of Pyruvate Kinase-R, Improves Sickle RBC Functional Health and Survival and Reduces Systemic Markers of Inflammation and Hypercoagulability in Patients with Sickle Cell Disease: An Analysis of Exploratory Studies in a Phase 1 Study. Kalfa, TA; Telen, MJ; Saraf, SL; Brown, RC C; Giger Seu, K; Larkin, SK; Ribadeneira, MD; Schroeder, P; Wu, E; Kelly, P; et al. Blood. 2021; 138:8-8.

Trial in Progress: A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of the PKR Activator Etavopivat (FT-4202) in Patients with Thalassemia or Sickle Cell Disease. Lal, A; Brown, RC C; Coates, TD; Kalfa, TA; Kwiatkowski, JL; Brevard, J; Potter, V; Wood, KW; Sheth, S. Blood. 2021; 138:4162-4162.

From the Blog



Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey